The Effects of Piroxicam and Deracoxib on Canine Mammary Tumour Cell Line

Table 1

Effects of piroxicam and deracoxib on cell cycle phase distribution of CMT-U27 cells. Data are expressed as mean values ± standard error of means shown with *𝑃<0.05 versus control group.

Drug concentrations	% G0/G1	% S	% G2/M
Control	45.23 ± 1.17	35.62 ± 2.57	19.16 ± 1.81
Piroxicam (50 μM)	55.93 ± 2.79	35.49 ± 1.92	8.58 ± 0.83
Piroxicam (100 μM)	58.44 ± 2.48	34.63 ± 2.25	6.93 ± 1.03
Piroxicam (250 μM)	70.31 ± 1.32	24.13 ± 2.06	5.56 ± 0.39
Piroxicam (500 μM)	80.22 ± 1.67*	8.46 ± 0.77*	11.32 ± 1.78
Piroxicam (1000 μM)	79.05 ± 2.19*	11.93 ± 0.84*	9.02 ± 0.51
Deracoxib (50 μM)	50.21 ± 2.55	41.35 ± 1.92	8.44 ± 1.10
Deracoxib (100 μM)	53.74 ± 2.12	42.51 ± 1.77	3.75 ± 0.29
Deracoxib (250 μM)	65.57 ± 1.45	15.04 ± 1.55	19.39 ± 1.29
Deracoxib (500 μM)	79.94 ± 2.14*	14.03 ± 2.37	6.03 ± 0.53
Deracoxib (1000 μM)	71.34 ± 2.36*	4.72 ± 0.85*	23.94 ± 2.26